Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Longboard Pharmaceuticals Inc (LBPH)

Longboard Pharmaceuticals Inc (LBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,195,171
  • Shares Outstanding, K 38,880
  • Annual Sales, $ 0 K
  • Annual Income, $ -54,420 K
  • 60-Month Beta 1.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.35
Trade LBPH with:

Options Overview Details

View History
  • Implied Volatility 136.51% ( +12.70%)
  • Historical Volatility 83.12%
  • IV Percentile 99%
  • IV Rank 100.00%
  • IV High 136.51% on 07/03/24
  • IV Low 76.64% on 05/23/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 209
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 1.22
  • Today's Open Interest 898
  • Open Int (30-Day) 673

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.46
  • Number of Estimates 3
  • High Estimate -0.41
  • Low Estimate -0.48
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +29.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.64 +104.03%
on 06/10/24
33.74 -5.42%
on 07/02/24
+12.98 (+68.57%)
since 06/03/24
3-Month
15.64 +104.03%
on 06/10/24
33.74 -5.42%
on 07/02/24
+13.79 (+76.10%)
since 04/03/24
52-Week
3.60 +786.39%
on 11/30/23
33.74 -5.42%
on 07/02/24
+24.89 (+354.56%)
since 07/03/23

Most Recent Stories

More News
5 Breakout Biotech Stocks Leading the Russell 2000 Higher

These small-cap biotech stocks are rallying hard in 2024, and still have room to keep leading the RUT higher.

JANX : 38.50 (-2.04%)
VKTX : 50.47 (-2.08%)
LBPH : 31.91 (+3.81%)
ARQT : 9.60 (+3.23%)
RNA : 37.21 (-4.10%)
Forget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher

You might say that this biotech stock is magnificent.

META : 509.96 (+0.09%)
MSFT : 460.77 (+0.32%)
GOOGL : 185.82 (+0.31%)
AAPL : 221.55 (+0.58%)
TSLA : 246.39 (+6.54%)
AMZN : 197.59 (-1.21%)
NVDA : 128.28 (+4.57%)
GOOG : 187.39 (+0.42%)
LBPH : 31.91 (+3.81%)
Longboard Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi...

LBPH : 31.91 (+3.81%)
Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update...

LBPH : 31.91 (+3.81%)
Longboard Pharmaceuticals to Report Full Year 2022 Financial Results and Key Corporate Initiatives on March 2, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans...

LBPH : 31.91 (+3.81%)
Longboard Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of...

LBPH : 31.91 (+3.81%)
Longboard Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of...

LBPH : 31.91 (+3.81%)
Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced...

LBPH : 31.91 (+3.81%)
Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline...

LBPH : 31.91 (+3.81%)
Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will...

LBPH : 31.91 (+3.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Longboard Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel, transformative medicines for neurological diseases. Longboard Pharmaceuticals Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 35.63
2nd Resistance Point 34.40
1st Resistance Point 33.16
Last Price 31.91
1st Support Level 30.69
2nd Support Level 29.46
3rd Support Level 28.22

See More

52-Week High 33.74
Last Price 31.91
Fibonacci 61.8% 22.23
Fibonacci 50% 18.67
Fibonacci 38.2% 15.11
52-Week Low 3.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar